Bioconnection Appoints Richard Sewalt As New Chief Commercial Officer

OSS, The Netherlands – 6 September 2024, BioConnection, a leading Dutch contract development and manufacturing organization (CDMO) in the pharmaceutical industry, today announced the appointment of Richard Sewalt as new Chief Commercial Officer [CCO]. With his extensive background and proven expertise, Richard will be a key driver of BioConnection’s success and growth.

Richard brings over more than 20 years of experience in the biopharmaceutical industry and global commercialization in a business-to-business environment. During his career he served in several increasingly senior commercial roles of which the last 10 years as Chief Commercial Officer at Synthon in the Netherlands and at Galenicum in Spain.

Richard graduated in Chemistry at the University of Amsterdam [cum laude] and holds a Ph.D in Biochemistry. The combination of his scientific background with his commercial and business mindset provides a unique combination for successful understanding of the end-to-end process of development, production and commercialization of medicines in the biopharmaceutical industry.

Richard Sewalt commented to his appointment:
"I am very excited to embark on this new journey and to further grow the company together with the whole team at BioConnection. In addition, I look forward to expanding the business and creating value for patients together with our current customers as well as with new customers."

BioConnection’s CEO Alexander Willemse, PhD, MSc stated:
“We are confident that Richard’s expertise and leadership will be instrumental in driving our future success.”

About BioConnection
BioConnection is a leading Dutch contract development and manufacturing organization (CDMO) serving the pharmaceutical industry. We specialize in the production of injectable (bio) pharmaceutical products, catering to a global clientele from our FDA and EMA-certified facility in Oss, North Brabant. Our comprehensive range of services includes Chemistry, Manufacturing, and Controls (CMC), encompassing drug product manufacturing process development, Fill & Finish for liquid, and freeze-drying (lyophilization) presentations at both clinical and commercial scales in vials and syringes. Additionally, we offer specialized small-scale (hand fill) production for personalized medicines, ensuring adaptability and precision in pharmaceutical manufacturing.

For further backgrounds, please contact
BioConnection, Oss, The Netherlands
T: +31-412 637 937
E: contact@bioconnection.eu
www.bioconnection.eu

For media:
LifeSpring Life Sciences Communication, Amsterdam
Leon Melens
T +31 6 538 16427
E: lmelens@lifespring.nl

First published on Fri, Sep 6, 2024

Enjoyed what you read? Great news – there’s a lot more to explore!

Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!

Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.

Head to the TechDogs homepage to Know Your World of technology today!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

BioConnection CDMO Pharmaceutical Industry Richard Sewalt Chief Commercial Officer Biopharmaceuticals Commercialization Synthon Galenicum

Join The Discussion

Applied Systems Builds On AI Reconciliation Momentum With New Financial Operations Innovation

Aureon And Partners Deliver 100-Terabit Route For The AI Era

Centerbase Selects Avidxchange As The Exclusive Partner To Power Embedded Payments

Infoblox Completes Axur Acquisition, Expands Preemptive Security To Stop External Threats At The Source

Lyrie.Ai Deploys Real-Time Zero-Day Tracking Across Global Enterprise Infrastructure